five-year disease-specific survival for the entire cohort was 34%, with a median follow-up of 39 months for survivors. Thirty-four (74%) of 46 patients relapsed, with a median relapse-free survival of 10 months and an overall recurrence rate of 53% at 1 year. The majority of patients developed distant recurrences. No differences were seen in patterns of relapse between patients treated with an ...